Association between CYP2C19*2 variant and clinical outcome in Clopidogrel treated patients from Republic of Macedonia

• 主要な著者: Aleksandra Kapedanovska Nestorovska (著者), Aleksandra Dimitrovska Cvetkovska (著者), Ljubica Suturkova (著者)
• フォーマット: 図書
• 出版事項: University Ss Cyril and Methodius in Skopje, Faculty of Pharmacy and Macedonian Pharmaceutical Association, 2011-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Clopidogrel is the thienopyridine of choice for prevention of ischemic events and stent thrombosis in patients with atherotrombotic disease. Recent studies suggest that certain genetic variants involving CYP450 system are responsible for wide interindividual variability in treatment response profile...